कंपनी का अवलोकन
Annovis Bio, Inc. operates as a clinical stage drug platform company dedicated to developing therapeutic agents for the treatment of neurodegeneration within the United States market. The entity functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at unmet medical needs. The company's total market capitalization stands at $45.94M, while its reported annual revenue is N/A, and the organization employs approximately 7 individuals. These financial and operational metrics indicate that Annovis Bio is a micro-cap entity with a very small workforce, suggesting that the entire enterprise's value is heavily concentrated in its intellectual property and pipeline assets rather than established commercial sales or a large operational infrastructure. The absence of significant annual revenue figures relative to its market cap highlights a typical pre-commercialization biotechnology profile where valuation is driven by potential future product candidates rather than current cash flows.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months report a net income of $-28,854,196, while the company's revenue is listed as N/A and its EBITDA is also N/A. The substantial negative net income in the absence of reported revenue reveals a cost structure characterized by significant operating expenses, likely driven by research and development costs, which have not yet been offset by product sales. Free cash flow for the period is reported at $-15,183,042, indicating that the company is consuming cash reserves to fund its ongoing clinical trials and operational activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated sufficient gross profit or operating income to cover its direct and indirect costs, a standard characteristic of early-stage development firms. In terms of liquidity and leverage, the company holds $19.53M in cash against $0 in debt, resulting in a debt-to-equity ratio that is N/A due to the lack of traditional equity capitalization in the denominator or the specific reporting context of N/A metrics. The current ratio stands at 5.80, which indicates a robust short-term liquidity position capable of covering current liabilities many times over, providing a buffer despite the cash burn. Return on Equity is reported at -220.6% and Return on Assets at -106.0%, revealing that management effectiveness in generating returns is currently negative as the company invests capital to build value rather than distributing it as profit.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the net losses, while the forward P/E is reported as -1.50, a negative figure that implies the market is pricing in an expectation of continued losses or is utilizing a non-standard calculation based on projected earnings that do not yet materialize. The price-to-book ratio is 2.61, indicating that the market values the company at a 161% premium over its net asset book value, which reflects the high valuation placed on its intangible assets such as patent rights and clinical data rather than tangible physical assets. The price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional valuation multiples based on sales or earnings are not applicable given the lack of revenue and earnings data. The stock price has fluctuated between a 52-week high of $5.50 and a 52-week low of $1.11, with the current trading position relative to this range requiring specific price input to calculate the exact percentage, though the wide spread indicates significant volatility typical of speculative biotech stocks. The beta value is 1.36, which explains that the stock price is expected to be 36% more volatile than the broader market, meaning it will likely amplify market movements both upwards and downwards during periods of economic change.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which precludes a direct comparison of growth rates between earnings and revenue. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate, and consequently, there is no sustainability concern regarding a payout ratio given the company's earnings. As a non-dividend payer, Annovis Bio reinvests its remaining resources and cash reserves entirely into research, development, and clinical trial progression rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on capital markets for funding and a focus on long-term product development milestones rather than immediate income generation or shareholder yield.